Contribution of acquired factors to the pathogenesis of dilated cardiomyopathy: The cause of dilated cardiomyopathy: Genetic or acquired? (acquired-side)

Circulation Journal

Volumn 75, Issue 7, 2011, Pages 1766-1773

  Yoshikawa, Tsutomu ^a  

^a SAKAKIBARA HEART INSTITUTE   (Japan)

Author keywords

Antibodies; Cytokines; Dilated cardiomyopathy; Genetics; Immune system; Myocarditis

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); AUTOANTIBODY; BETA 1 ADRENERGIC RECEPTOR; CARDIAC MYOSIN; HEART ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MUSCARINIC M2 RECEPTOR; TROPONIN I;

ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CALCIUM CURRENT; CELL DAMAGE; CELLULAR IMMUNITY; CHRONIC DISEASE; CONGESTIVE CARDIOMYOPATHY; GENETIC DISORDER; HEART ATRIUM FIBRILLATION; HEART MUSCLE CELL; HEART MUSCLE INJURY; HEART VENTRICLE ARRHYTHMIA; HEREDITY; HUMAN; HUMORAL IMMUNITY; INFECTION SENSITIVITY; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; SUDDEN DEATH; SUPPRESSOR CELL; TARGET ORGAN; VIRUS GENOME; VIRUS INFECTION; VIRUS MYOCARDITIS;

CARDIOMYOPATHY, DILATED; DISEASE SUSCEPTIBILITY; HUMANS; MUTATION;

EID: 79959694904     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-0373     Document Type: Article

References (54)

1. Miura K, Matsumori A, Nasermoaddeli A, Soyama Y, Morikawa Y, Sakurai M, et al. Prognosis and prognostic factors in patients with idiopathic dilated cardiomyopathy in Japan. Circ J 2008; 72: 343-348.
2. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, et al. Contemporary definitions and classification of the cardiomyopathies. Circulation 2006; 113: 1807-1816.
3. Elliott P, Anderson B, Arbustini E, Bilinska Z, Cecchi F, Charron F, et al. Classification of the cardiomyopathies: A position from the European Society of Cardiology working group on myocardial and pericardial diseases. Eur Heart J 2008; 29: 270-276.
4. Matsumori A. Hepatitis C virus infection and cardiomyopathies. Circ Res 2005; 96: 144-147.
5. Ukimura A, Izumi T, Matsumori A. A national survey on myocarditis associated with the 2009 influenza A (H1N1) pandemic in Japan. Circ J 2010; 74: 2193-2199.
6. Badorff C, Lee CH, Lamphear BJ, Martone ME, Camphell KP, Rhoads RE, et al. Enteroviral protease 2A cleaves dystrophin: Evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med 1999; 5: 320-326.
7. Xiong D, Yajima T, Lim BK, Stenbit A, Dalton ND, Summers- Torres D, et al. Inducible cardiac-restricted expression of enteroviral protease 2A is sufficient to induce dilated cardiomyopathy. Circulation 2007; 115: 94-102.
8. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000; 342: 1077-1084.
9. Wessely R, Klingel K, Knowton KU, Kandolf R. Cardioselective infection with coxsackievirus B3 requires intact type I interferon signaling: Implications for mortality and early viral replication. Circulation 2001; 103: 756-761.
10. Opavsky MA, Penninger J, Aitken K, Wen K, Dawood F, Mak T, et al. Susceptibility to myocarditis is dependent on the response of α β T lymphocytes to coxsackieviral infection. Circ Res 1999; 85: 551-558.
11. Liu P, Aitken K, Kong YY, Opavsky MA, Martino T, Dawood F, et al. Essential role for the tyrosine kinase p56lck in coxsackievirus B3 mediated heart disease. Nat Med 2000; 6: 429-434.
12. Irie-Sasaki J, Sasaki T, Matsumoto W, Opavsky A, Cheng M, Weistead G, et al. CD45 is a JAK phosphatase and negatively regulates cytokine receptor signaling. Nature 2001; 409: 349-354.
13. Opavsky MA, Martino T, Rabinovitch M, Penninger J, Richardson C, Petric M, et al. Enhanced ERK-1/2 activation in mice susceptible to coxsackievirus-induced myocarditis. J Clin Invest 2002; 109: 1561-1569.
14. Shi Y, Fukuoka M, Li G, Liu Y, Chen M, Konviser M, et al. Regulatory T cells protect mice against coxsackievirus-induced myocarditis through the transforming growth factor beta-coxsackie-adenovirus receptor pathway. Circulation 2010; 121: 2624-2634.
15. Baldeviano GC, Barin JG, Talor MV, Srinivasan S, Bedja D, Zheng D, et al. Interleukin-17A is dispensable for myocarditis but essential for the progression to dilated cardiomyopathy. Circ Res 2010; 106: 1646-1655.
16. Kühl U, Pauschinger M, Noutsias M, Seeberg B, Bock T, Lassner D, et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with "idiopathic" left ventricular dysfunction. Circulation 2005; 111: 887-893.
17. Bowles NE, Ni J, Kearney DL, Pauschinger M, Schultheiss HP, McCarthy R, et al. Detection of viruses in myocardial tissues by polymerase chain reaction: Evidence of adenovirus as a common cause of myocarditis in children and adults. J Am Coll Cardiol 2003; 42: 466-472.
18. Kühl U, Pauschinger M, Seeberg B, Lassner D, Noutsias M, Poller W, et al. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 2005; 112: 1965-1970.
19. Kühl U, Pauschinger M, Schwimmbeck PL, Seeberg B, Lober C, Noutsias M, et al. Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 2003; 107: 2793-2798.
20. Wessely R, Klingel K, Santana LF, Dalton N, Hongo M, Jonathan Lederer W, et al. Transgenic expression of replication-restricted enteroviral genomes in heart muscle induces defective excitationcontraction coupling and dilated cardiomyopathy. J Clin Invest 1998; 102: 1444-1453.
21. Kindermann I, Kindermann M, Kandolf R, Klingel K, Bültmann B, Müller T, et al. Predictors of outcome in patients with suspected myocarditis. Circulation 2008; 118: 639-648.
22. Wucherpfennig KW, Strominger JL. Molecular mimicry in T cellmediated autoimmunity: Viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995; 80: 695-705.
23. Smith SC, Allen P. Myosin-induced acute myocarditis is a T cellmediated disease. J Immunol 1991; 147: 2141-2147.
24. Baba A, Yoshikawa T, Chino M, Murayama A, Mitani K, Nakagawa S, et al. Characterization of anti-myocardial autoantibodies in Japanese patients with dilated cardiomyopathy. Jpn Circ J 2001; 65: 867-873.
25. Yoshikawa T, Baba A, Nagatomo Y. Autoimmune mechanisms underlying dilated cardiomyopathy. Circ J 2009; 73: 602-607.
26. Caforio ALP, Mahon NG, Baig MK, Tona F, Murphy RT, Elliott PM, et al. Prospective familial assessment in dilated cardiomyopathy: Cardiac autoantibodies predict disease development in asymptomatic relatives.Circulation 2007; 115: 76-83.
27. Baba A, Akaishi M, Shimada M, Monkawa T, Wakabayashi Y, Takahashi M, et al. Complete elimination of cardiodepressant IgG3 autoantibodies by immunoadsorption in patients with severe heart failure. Circ J 2010; 74: 1372-1378.
28. Caforio AL, Grazzini M, Mann JM, Keeling PJ, Bottazzo GF, McKenna WJ, et al. Identification of alpha- and beta-cardiac myosin heavy chain isoforms as major autoantigens in dilated cardiomyopathy. Circulation 1992; 85: 1734-1742.
29. Lauer B, Schanwell M, Kühl U, Strauer BE, Schultheiss HP. Antimyosin autoantibodies are associated with deterioration of systolic and diastolic left ventricular function in patients with chronic myocarditis. J Am Coll Cardiol 2000; 35: 11-18.
30. Galvin JE, Hemric ME, Kosanke SD, Factor SM, Quinn A, Cunningham MW. Induction of myocarditis and valvulitis in Lewis rats by different epitopes of cardiac myosin and its implications in rheumatic carditis. Am J Pathol 2002; 160: 297-306.
31. Kuan AP, Chamberlain W, Malkiel S, Lieu HD, Factor SM, Diamond B, et al. Genetic control of autoimmune myocarditis mediated by myosin-specific antibodies. Immunogenetics 1999; 49: 79-85.
32. Magnusson Y, Wallukat G, Waagstein F, Hjalmarson Å, Hoebeke J. Autoimmunity in idiopathic dilated cardiomyopathy: Characterization of antibodies against the beta 1-adrenoceptor with positive chronotropic effect. Circulation 1994; 89: 2760-2767.
33. Podlowski S, Luther HP, Morwinski R, Müller J, Wallukat G. Agonistic anti-beta1-adrenergic receptor autoantibodies from cardiomyopathy patients reduce the beta1-adrenergic receptor expression in neonatal rat cardiomyocytes. Circulation 1998; 98: 2470-2476.
34. Iwata M, Yoshikawa T, Baba A, Anzai T, Nakamura I, Wainai Y, et al. Autoimmunity against the second extracellular loop of beta(1)- adrenergic receptors induces beta-adrenergic receptor desensitization and myocardial hypertrophy in vivo. Circ Res 2001; 88: 578-586.
35. Jahns R, Boivin V, Hein L, Triebel S, Angermann CE, Ertl G, et al. Direct evidence for a beta 1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest 2004; 113: 1419-1429.
36. Liu J, Mao W, Iwai C, Fukuoka S, Vulapalli R, Huang H, et al. Adoptive passive transfer of rabbit beta1-adrenoceptor peptide immune cardiomyopathy into the Rag2-/- mouse: Participation of the ER stress. J Mol Cell Cardiol 2008; 44: 304-314.
37. Jahns R, Boivin V, Siegmund C, Inselmann G, Lohse MJ, Boege F. Autoantibodies activating human beta1-adrenergic receptors are associated with reduced cardiac function in chronic heart failure. Circulation 1999; 99: 649-654.
38. Störk S, Boivin V, Horf R, Hein L, Lohse MJ, Angermann CE, et al. Stimulating autoantibodies directed against the cardiac beta1-adrenergic receptor predict increased mortality in idiopathic cardiomyopathy. Am Heart J 2006; 152: 697-704.
39. Iwata M, Yoshikawa T, Baba A, Anzai T, Mitamura H, Ogawa S. Autoantibodies against the second extracellular loop of beta1-adrenergic receptors predict ventricular tachycardia and sudden death in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2001; 37: 418-424.
40. Fukuda Y, Miyoshi S, Tanimoto K, Oota K, Fujikura K, Iwata M, et al. Autoimmunity against the second extracellular loop of beta(1)- adrenergic receptors induces early afterdepolarization and decreases in K-channel density in rabbits. J Am Coll Cardiol 2004; 43: 1090-1100.
41. Baba A, Yoshikawa T, Fukuda Y, Sugiyama T, Shimada M, Akaishi M, et al. Autoantibodies against M2-muscarinic acetylcholine receptors: New upstream targets in atrial fibrillation in patients with dilated cardiomyopathy. Eur Heart J 2004; 25: 1108-1115.
42. Baba A, Yoshikawa T, Ogawa S. Autoantibodies produced against sarcolemmal Na-K-ATPase: Possible upstream targets of arrhythmias and sudden death in patients with dilated cardiomyopathy. J Am Coll Cardiol 2002; 40: 1153-1159.
43. Baba A, Yoshikawa T, Iwata M, Anzai T, Nakamura I, Wainai Y, et al. Antigen-specific effects of autoantibodies against sarcolemmal Na-K-ATPase pump in immunized cardiomyopathic rabbits. Int J Cardiol 2006; 112: 15-20.
44. Okazaki T, Tanaka Y, Nishio R, Mitsuiye T, Mizoguchi A, Wang J, et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 2003; 9: 1477-1483.
45. Limas CJ, Iakovis P, Anyfantakis A, Kroupis C, Cokkinos DV. Familial clustering of autoimmune diseases in patients with dilated cardiomyopathy. Am J Cardiol 2004; 93: 1189-1191.
46. Liu W, Li WM, Sun NL. HLA-DQA1, -DQB1 polymorphism and genetic susceptibility to idiopathic dilated cardiomyopathy in Hans of northern China. Ann Hum Genet 2005; 69: 382-388.
47. Lozano MD, Rubocki RJ, Wilson JE, McManus BM, Wisecarver JL. Human leukocyte antigen class II associations in patients with idiopathic dilated cardiomyopathy: Myocarditis Treatment Trial Investigators. J Card Fail 1997; 3: 97-103.
48. Zhang L, Hu A, Yuan H, Cui L, Miao G, Yang X, et al. A missense mutation in the CHRM2 gene is associated with familial dilated cardiomyopathy. Circ Res 2008; 102: 1426-1432.
49. Xiong D, Lee GH, Bardoff C, Dorner A, Lee S, Wolf P, et al. Dystrophin deficiency markedly increases enterovirus-induced cardiomyopathy: A genetic predisposition to viral heart disease. Nat Med 2002; 8: 872-877.
50. Michels VV, Moll PP, Miller FA, Tajik AJ, Chu JS, Driscoll DJ, et al. The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N Engl J Med 1992; 326: 77-82.
51. Arber S, Hunter JJ, Ross J Jr, Hongo M, Sansig G, Borg J, et al. MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell 1997; 88: 393-403.
52. Schmitt JP, Kamisago M, Asahi M, Li GH, Ahmad F, Mende U, et al. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 2003; 299: 1410-1413.
53. Nikolova V, Leimena C, McMahon AC, Tan JC, Chandar S, Jogia D, et al. Defects in nuclear structure and function promote dilated cardiomyopathy in lamin A/C-deficient mice. J Clin Invest 2004; 113: 357-369.
54. Kimura A. Contribution of genetic factors to the pathogenesis of dilated cardiomyopathy: The cause of dilated cardiomyopathy: Genetic or acquired? (Genetic-Side) Circ J 2011; 75: 1756-1765.